Medicine,
Journal Year:
2023,
Volume and Issue:
102(43), P. e35438 - e35438
Published: Oct. 27, 2023
Using
network
pharmacology,
molecular
docking,
and
microRNA
recognition,
we
have
elucidated
the
mechanisms
underlying
treatment
of
asthma
by
Jinxin
oral
liquid
(JXOL).
We
began
identifying
normalizing
active
compounds
in
JXOL
through
searches
traditional
Chinese
medicine
systems
pharmacology
database,
SwissADME
encyclopedia
HERB
PubChem.
Subsequently,
gathered
standardized
targets
these
from
sources
including
similarity
ensemble
approach
dataset,
UniProt,
other
databases.
Disease
were
extracted
GeneCards,
PharmGKB,
OMIM,
comparative
toxicogenomics
DisGeNET.
The
intersection
between
was
determined
using
a
Venn
diagram.
visualized
Formula-Herb-Compound-Target-Disease
protein-protein
interaction
Cytoscape
3.9.0.
Molecular
docking
studies
performed
Schrodinger
software.
To
identify
pathways
related
to
asthma,
conducted
gene
ontology
functional
analysis
Kyoto
genes
genomes
pathway
enrichment
Metascape.
MicroRNAs
regulating
hub
obtained
miRTarBase
linking
miRNAs
constructed.
Finally,
found
88
bioactive
components
218
common
with
asthma.
showed
key
strongly
bind
HUB
targets.
According
biological
process
analysis,
PI3K-Akt
signaling
pathway,
MAPK
or
cAMP
play
role
treating
JXOL.
target-miRNA
that
6
recognized.
In
our
study,
revealed
for
first
time
unique
components,
multiple
targets,
diverse
underlie
its
mechanism
action
miRNAs.
Cells,
Journal Year:
2023,
Volume and Issue:
12(19), P. 2421 - 2421
Published: Oct. 9, 2023
Respiratory
diseases
represent
a
significant
economic
and
health
burden
worldwide,
affecting
millions
of
individuals
each
year
in
both
human
animal
populations.
MicroRNAs
(miRNAs)
play
crucial
roles
gene
expression
regulation
are
involved
various
physiological
pathological
processes.
Exosomal
miRNAs
cellular
have
been
identified
as
key
regulators
several
immune
respiratory
diseases,
such
chronic
(CRD)
caused
by
Mycoplasma
gallisepticum
(MG),
pneumoniae
pneumonia
(MMP)
the
bacterium
pneumoniae,
coronavirus
disease
2019
(COVID-19),
obstructive
pulmonary
(COPD),
asthma,
acute
lung
injury/acute
distress
syndrome
(ALI/ARDS).
Consequently,
seem
to
potential
serve
diagnostic
biomarkers
therapeutic
targets
diseases.
In
this
review,
we
summarize
current
understanding
functional
above
discuss
use
stable
for
focusing
on
identification
differentially
expressed
their
targeting
signaling
pathways
implicated
pathogenesis.
Despite
progress
made,
unanswered
questions
future
research
directions
discussed
facilitate
personalized
targeted
therapies
patients
with
these
debilitating
conditions.
Cells,
Journal Year:
2025,
Volume and Issue:
14(2), P. 104 - 104
Published: Jan. 12, 2025
Asthma
is
a
major
non-communicable
disease
whose
pathogenesis
still
not
fully
elucidated.
One
of
the
asthma
research
models
precision-cut
lung
slices
(PCLSs),
and
among
therapeutic
options,
miRNA
molecules
are
great
interest.
The
aim
our
study
was
to
investigate
whether
inhibition
miR-223-3p
miR328a-3p
affects
inflammatory
response
in
PCLSs
derived
from
rat
with
HDM-induced
allergic
inflammation
control
rat.
We
generated
transfected
them
miR-328a-3p
inhibitors.
RNA
isolated
analyzed
by
qPCR.
also
examined
proteins
culture
medium
using
Magnetic
Luminex
Assay.
comparison
between
miRNA-transfected
non-transfected
controls
showed
significant
differences
expression
several
genes
associated
inflammation,
including
Il-33,
Ccl5,
Prg2
Tslp,
both
In
medium,
we
found
no
protein
levels
control.
Our
highlighted
some
important
issues:
need
extend
model
more
biological
replicates,
standardize
conditions,
consider
co-transfection
inhibitors
when
modifying
miRNAs
PCLS
model.
International Journal of Molecular Sciences,
Journal Year:
2025,
Volume and Issue:
26(8), P. 3570 - 3570
Published: April 10, 2025
Asthma
and
atherosclerosis
are
chronic
conditions
with
distinct
pathophysiologies,
but
overlapping
inflammatory
mechanisms
that
suggest
a
potential
common
regulatory
framework.
MicroRNAs
(miRNAs),
small
non-coding
RNA
molecules
modulate
gene
expression
post-transcriptionally,
could
be
key
players
in
linking
these
disorders.
This
review
outlines
how
miRNAs
contribute
to
the
complex
interplay
between
asthma
atherosclerosis,
focusing
on
involved
pathways,
immune
cell
regulation
vascular
remodeling.
We
discuss
specific
miRNAs,
such
as
miR-155,
miR-21
miR-146a,
which
have
been
shown
cytokine
production
T
differentiation,
impacting
respiratory
cardiovascular
health.
The
found
both
emphasize
their
role
biomarkers,
also
therapeutic
targets.
Understanding
molecular
connections
may
unlock
novel
approaches
for
innovative,
integrated
treatment
strategies
address
significantly
improve
patient
outcomes.
Further
research
is
needed
explore
mechanistic
pathways
validate
translational
of
miRNA-based
interventions
preclinical
clinical
settings.
International Journal of Molecular Sciences,
Journal Year:
2023,
Volume and Issue:
24(14), P. 11499 - 11499
Published: July 15, 2023
Asthma
is
a
chronic
inflammatory
disease
of
the
airways
characterized
by
shortness
breath,
chest
tightness,
coughing,
and
wheezing.
For
several
decades
(approximately
30
years),
miRNAs
their
role
in
asthma
have
been
constant
interest
among
scientists.
These
small,
non-coding
RNA
fragments,
18–25
nucleotides
long,
regulate
gene
expression
at
post-transcriptional
level
binding
to
target
mRNA.
In
this
way,
they
affect
biological
processes,
e.g.,
shaping
airway
structures,
producing
cytokines
immune
mediators,
controlling
defense
mechanisms.
Publications
confirm
potential
diagnosis
monitoring
disease,
but
only
some
articles
address
use
treatment
asthma.
The
following
paper
reviews
latest
available
studies
presents
as
useful
tool
for
predicting
effectiveness
included
treatment,
early
exacerbations,
assessing
patient
compliance
different
groups
drugs
used
known
pathways
underlying
pathogenesis
which
are
associated
with
change
miRNA
expression,
may
be
precise
targets
therapeutic
activity
future.
